search
Back to results

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
metformin
linagliptin
metformin placebo
metformin placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation / Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
  2. Male and female patients, 18 years of age or older at Visit 1 (Screen), with newly diagnosed (less than 12 months prior to Screen) Type 2 Diabetes Mellitus.
  3. Patients who are treatment-naïve, defined as absence of any oral antidiabetic therapy, injectable glucagon-like peptide-1 agonist/analogue, or insulin, and uncontrolled for the 12 weeks prior to randomisation.
  4. Patients must have an glycated (or glycosylated) haemoglobin (HbA1c) between 8.5% [69 millimoles per mole (mmol/mol)] and 12.0% (108 mmol/mol) at Visit 1 (Screen).
  5. Patients must have a Body Mass Index (BMI) of 45 kg/m2 or less at Visit 1 (Screen).
  6. In the investigators opinion, patients must be reliable, honest, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.

Exclusion criteria:

Patients with, who are, who have, or who have had:

  1. Acute coronary syndrome (non-ST Elevation Myocardial Infarction (STEMI), STEMI, and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent.
  2. Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the upper limit of normal (ULN) in any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase. Gilbert-Meulengracht syndrome (also known as conjugated hyperbilirubinemia, constitutional hepatic dysfunction, or familial nonhemolytic jaundice) will be permitted.
  3. Impaired renal function, defined as calculated creatinine clearance of less than 60 milliliters per minute (< 60 mL/min), by the Cockcroft-Gault Equation, as determined during Screen and/or Run-In Period.
  4. Bariatric, gastric bypass, and other gastrointestinal surgeries (including all types of gastric banding and/or LapBand) within the past two years.
  5. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  6. Medical history of pancreatitis.
  7. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, haemolytic anaemia).
  8. Any contraindication to metformin and/or linagliptin therapies, according to local labels.
  9. Treatment with anti-obesity drugs, including over-the-counter drugs such as Alli (orlistat), 3 months prior to informed consent or any other treatment at the time of screening (i.e., surgery, aggressive diet regimen, etc.) leading to unstable body weight.
  10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes Mellitus.
  11. Pre-menopausal women (last menstruation of 1 year or less prior to informed consent) who are nursing or pregnant, are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the trial and do not agree to submit to periodic pregnancy testing during participation in the trial.

    Note: Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable, intra-vaginal, or injectable contraceptives, Essure micro-inserts placed more than six months prior to Screen Visit, complete sexual abstinence (if acceptable by local authorities), double barrier method (e.g., diaphragm or condom and spermicide), and vasectomised partner.

  12. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance to trial procedures or study medication intake in the opinion of the investigator.
  13. Participation in another trial with an investigational drug within 2 months prior to informed consent.
  14. Any other clinical condition that would jeopardize patient safety while participating in this clinical trial in the opinion of the Investigator.
  15. Inability to commit to regular overnight fasting of at least 10 hours duration and attendance to study site visits between 07:00 and 11:00 ante meridiem (a.m.).

Sites / Locations

  • 1218.83.11002 Boehringer Ingelheim Investigational Site
  • 1218.83.11036 Boehringer Ingelheim Investigational Site
  • 1218.83.11011 Boehringer Ingelheim Investigational Site
  • 1218.83.11001 Boehringer Ingelheim Investigational Site
  • 1218.83.11019 Boehringer Ingelheim Investigational Site
  • 1218.83.11015 Boehringer Ingelheim Investigational Site
  • 1218.83.11023 Boehringer Ingelheim Investigational Site
  • 1218.83.11014 Boehringer Ingelheim Investigational Site
  • 1218.83.11031 Boehringer Ingelheim Investigational Site
  • 1218.83.11022 Boehringer Ingelheim Investigational Site
  • 1218.83.11025 Boehringer Ingelheim Investigational Site
  • 1218.83.11033 Boehringer Ingelheim Investigational Site
  • 1218.83.11029 Boehringer Ingelheim Investigational Site
  • 1218.83.11026 Boehringer Ingelheim Investigational Site
  • 1218.83.11008 Boehringer Ingelheim Investigational Site
  • 1218.83.11027 Boehringer Ingelheim Investigational Site
  • 1218.83.11005 Boehringer Ingelheim Investigational Site
  • 1218.83.11013 Boehringer Ingelheim Investigational Site
  • 1218.83.11028 Boehringer Ingelheim Investigational Site
  • 1218.83.11009 Boehringer Ingelheim Investigational Site
  • 1218.83.11003 Boehringer Ingelheim Investigational Site
  • 1218.83.11024 Boehringer Ingelheim Investigational Site
  • 1218.83.11018 Boehringer Ingelheim Investigational Site
  • 1218.83.11004 Boehringer Ingelheim Investigational Site
  • 1218.83.11017 Boehringer Ingelheim Investigational Site
  • 1218.83.11032 Boehringer Ingelheim Investigational Site
  • 1218.83.11030 Boehringer Ingelheim Investigational Site
  • 1218.83.11034 Boehringer Ingelheim Investigational Site
  • 1218.83.11021 Boehringer Ingelheim Investigational Site
  • 1218.83.12011 Boehringer Ingelheim Investigational Site
  • 1218.83.12007 Boehringer Ingelheim Investigational Site
  • 1218.83.12001 Boehringer Ingelheim Investigational Site
  • 1218.83.12002 Boehringer Ingelheim Investigational Site
  • 1218.83.12009 Boehringer Ingelheim Investigational Site
  • 1218.83.12005 Boehringer Ingelheim Investigational Site
  • 1218.83.12006 Boehringer Ingelheim Investigational Site
  • 1218.83.12003 Boehringer Ingelheim Investigational Site
  • 1218.83.12010 Boehringer Ingelheim Investigational Site
  • 1218.83.12012 Boehringer Ingelheim Investigational Site
  • 1218.83.91003 Boehringer Ingelheim Investigational Site
  • 1218.83.91005 Boehringer Ingelheim Investigational Site
  • 1218.83.91001 Boehringer Ingelheim Investigational Site
  • 1218.83.97004 Boehringer Ingelheim Investigational Site
  • 1218.83.97005 Boehringer Ingelheim Investigational Site
  • 1218.83.97007 Boehringer Ingelheim Investigational Site
  • 1218.83.60001 Boehringer Ingelheim Investigational Site
  • 1218.83.60002 Boehringer Ingelheim Investigational Site
  • 1218.83.60003 Boehringer Ingelheim Investigational Site
  • 1218.83.52004 Boehringer Ingelheim Investigational Site
  • 1218.83.52001 Boehringer Ingelheim Investigational Site
  • 1218.83.52002 Boehringer Ingelheim Investigational Site
  • 1218.83.52005 Boehringer Ingelheim Investigational Site
  • 1218.83.52003 Boehringer Ingelheim Investigational Site
  • 1218.83.63007 Boehringer Ingelheim Investigational Site
  • 1218.83.63001 Boehringer Ingelheim Investigational Site
  • 1218.83.63008 Boehringer Ingelheim Investigational Site
  • 1218.83.63003 Boehringer Ingelheim Investigational Site
  • 1218.83.63002 Boehringer Ingelheim Investigational Site
  • 1218.83.63006 Boehringer Ingelheim Investigational Site
  • 1218.83.63004 Boehringer Ingelheim Investigational Site
  • 1218.83.11037 Boehringer Ingelheim Investigational Site
  • 1218.83.07001 Boehringer Ingelheim Investigational Site
  • 1218.83.07002 Boehringer Ingelheim Investigational Site
  • 1218.83.07004 Boehringer Ingelheim Investigational Site
  • 1218.83.07006 Boehringer Ingelheim Investigational Site
  • 1218.83.07003 Boehringer Ingelheim Investigational Site
  • 1218.83.07007 Boehringer Ingelheim Investigational Site
  • 1218.83.07005 Boehringer Ingelheim Investigational Site
  • 1218.83.94004 Boehringer Ingelheim Investigational Site
  • 1218.83.94002 Boehringer Ingelheim Investigational Site
  • 1218.83.94003 Boehringer Ingelheim Investigational Site
  • 1218.83.94001 Boehringer Ingelheim Investigational Site
  • 1218.83.66002 Boehringer Ingelheim Investigational Site
  • 1218.83.66003 Boehringer Ingelheim Investigational Site
  • 1218.83.66001 Boehringer Ingelheim Investigational Site
  • 1218.83.38007 Boehringer Ingelheim Investigational Site
  • 1218.83.38001 Boehringer Ingelheim Investigational Site
  • 1218.83.38006 Boehringer Ingelheim Investigational Site
  • 1218.83.38004 Boehringer Ingelheim Investigational Site
  • 1218.83.38008 Boehringer Ingelheim Investigational Site
  • 1218.83.38003 Boehringer Ingelheim Investigational Site
  • 1218.83.38005 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

linagliptin

linagliptin plus metformin

Arm Description

patients receive linagliptin tablet once daily

patients receive linagliptin tablet once daily and metformin tablets twice daily

Outcomes

Primary Outcome Measures

Change From Baseline in HbA1c After 24 Weeks
HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c

Secondary Outcome Measures

Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
Change From Baseline in HbA1c by Visit Over Time
HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)
The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)
The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.
Occurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment
The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.
Change From Baseline in FPG by Visit Over Time
The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.

Full Information

First Posted
January 16, 2012
Last Updated
May 12, 2014
Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01512979
Brief Title
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
Official Title
A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naïve, Uncontrolled Type 2 Diabetes Mellitus Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
Collaborators
Eli Lilly and Company

4. Oversight

5. Study Description

Brief Summary
The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
316 (Actual)

8. Arms, Groups, and Interventions

Arm Title
linagliptin
Arm Type
Experimental
Arm Description
patients receive linagliptin tablet once daily
Arm Title
linagliptin plus metformin
Arm Type
Experimental
Arm Description
patients receive linagliptin tablet once daily and metformin tablets twice daily
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Description
1000 mg to 2000 mg per day
Intervention Type
Drug
Intervention Name(s)
linagliptin
Intervention Description
5 mg daily
Intervention Type
Drug
Intervention Name(s)
metformin placebo
Intervention Description
0 to 2 tablets daily
Intervention Type
Drug
Intervention Name(s)
metformin placebo
Intervention Description
4 tablets daily
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c After 24 Weeks
Description
HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c
Time Frame
Baseline and 24 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
Description
The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.
Time Frame
Baseline and 24 weeks
Title
Change From Baseline in HbA1c by Visit Over Time
Description
HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.
Time Frame
Baseline, 6, 12, 18 and 24 weeks
Title
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)
Description
The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.
Time Frame
Baseline and 24 weeks
Title
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)
Description
The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.
Time Frame
Baseline and 24 weeks
Title
Occurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment
Description
The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.
Time Frame
Baseline and 24 weeks
Title
Change From Baseline in FPG by Visit Over Time
Description
The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.
Time Frame
Baseline, 6, 12, 18 and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Patients must sign and date an Informed Consent consistent with International Conference on Harmonisation / Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial. Male and female patients, 18 years of age or older at Visit 1 (Screen), with newly diagnosed (less than 12 months prior to Screen) Type 2 Diabetes Mellitus. Patients who are treatment-naïve, defined as absence of any oral antidiabetic therapy, injectable glucagon-like peptide-1 agonist/analogue, or insulin, and uncontrolled for the 12 weeks prior to randomisation. Patients must have an glycated (or glycosylated) haemoglobin (HbA1c) between 8.5% [69 millimoles per mole (mmol/mol)] and 12.0% (108 mmol/mol) at Visit 1 (Screen). Patients must have a Body Mass Index (BMI) of 45 kg/m2 or less at Visit 1 (Screen). In the investigators opinion, patients must be reliable, honest, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them. Exclusion criteria: Patients with, who are, who have, or who have had: Acute coronary syndrome (non-ST Elevation Myocardial Infarction (STEMI), STEMI, and unstable angina pectoris), stroke or transient ischemic attack within 3 months prior to informed consent. Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the upper limit of normal (ULN) in any of the following: alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase. Gilbert-Meulengracht syndrome (also known as conjugated hyperbilirubinemia, constitutional hepatic dysfunction, or familial nonhemolytic jaundice) will be permitted. Impaired renal function, defined as calculated creatinine clearance of less than 60 milliliters per minute (< 60 mL/min), by the Cockcroft-Gault Equation, as determined during Screen and/or Run-In Period. Bariatric, gastric bypass, and other gastrointestinal surgeries (including all types of gastric banding and/or LapBand) within the past two years. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years. Medical history of pancreatitis. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, haemolytic anaemia). Any contraindication to metformin and/or linagliptin therapies, according to local labels. Treatment with anti-obesity drugs, including over-the-counter drugs such as Alli (orlistat), 3 months prior to informed consent or any other treatment at the time of screening (i.e., surgery, aggressive diet regimen, etc.) leading to unstable body weight. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes Mellitus. Pre-menopausal women (last menstruation of 1 year or less prior to informed consent) who are nursing or pregnant, are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the trial and do not agree to submit to periodic pregnancy testing during participation in the trial. Note: Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable, intra-vaginal, or injectable contraceptives, Essure micro-inserts placed more than six months prior to Screen Visit, complete sexual abstinence (if acceptable by local authorities), double barrier method (e.g., diaphragm or condom and spermicide), and vasectomised partner. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance to trial procedures or study medication intake in the opinion of the investigator. Participation in another trial with an investigational drug within 2 months prior to informed consent. Any other clinical condition that would jeopardize patient safety while participating in this clinical trial in the opinion of the Investigator. Inability to commit to regular overnight fasting of at least 10 hours duration and attendance to study site visits between 07:00 and 11:00 ante meridiem (a.m.).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.83.11002 Boehringer Ingelheim Investigational Site
City
Phoenix
State/Province
Arizona
Country
United States
Facility Name
1218.83.11036 Boehringer Ingelheim Investigational Site
City
Little Rock
State/Province
Arkansas
Country
United States
Facility Name
1218.83.11011 Boehringer Ingelheim Investigational Site
City
Chino
State/Province
California
Country
United States
Facility Name
1218.83.11001 Boehringer Ingelheim Investigational Site
City
Huntington Beach
State/Province
California
Country
United States
Facility Name
1218.83.11019 Boehringer Ingelheim Investigational Site
City
Huntington Park
State/Province
California
Country
United States
Facility Name
1218.83.11015 Boehringer Ingelheim Investigational Site
City
Lomita
State/Province
California
Country
United States
Facility Name
1218.83.11023 Boehringer Ingelheim Investigational Site
City
Norwalk
State/Province
California
Country
United States
Facility Name
1218.83.11014 Boehringer Ingelheim Investigational Site
City
Roseville
State/Province
California
Country
United States
Facility Name
1218.83.11031 Boehringer Ingelheim Investigational Site
City
San Diego
State/Province
California
Country
United States
Facility Name
1218.83.11022 Boehringer Ingelheim Investigational Site
City
Fort Lauderdale
State/Province
Florida
Country
United States
Facility Name
1218.83.11025 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1218.83.11033 Boehringer Ingelheim Investigational Site
City
Sanford
State/Province
Florida
Country
United States
Facility Name
1218.83.11029 Boehringer Ingelheim Investigational Site
City
Oakwood
State/Province
Georgia
Country
United States
Facility Name
1218.83.11026 Boehringer Ingelheim Investigational Site
City
Owensboro
State/Province
Kentucky
Country
United States
Facility Name
1218.83.11008 Boehringer Ingelheim Investigational Site
City
Elkton
State/Province
Maryland
Country
United States
Facility Name
1218.83.11027 Boehringer Ingelheim Investigational Site
City
Freemont
State/Province
Nebraska
Country
United States
Facility Name
1218.83.11005 Boehringer Ingelheim Investigational Site
City
Edison
State/Province
New Jersey
Country
United States
Facility Name
1218.83.11013 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
North Carolina
Country
United States
Facility Name
1218.83.11028 Boehringer Ingelheim Investigational Site
City
Salisbury
State/Province
North Carolina
Country
United States
Facility Name
1218.83.11009 Boehringer Ingelheim Investigational Site
City
Shelby
State/Province
North Carolina
Country
United States
Facility Name
1218.83.11003 Boehringer Ingelheim Investigational Site
City
Franklin
State/Province
Ohio
Country
United States
Facility Name
1218.83.11024 Boehringer Ingelheim Investigational Site
City
Gallipolis
State/Province
Ohio
Country
United States
Facility Name
1218.83.11018 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
South Carolina
Country
United States
Facility Name
1218.83.11004 Boehringer Ingelheim Investigational Site
City
Bristol
State/Province
Tennessee
Country
United States
Facility Name
1218.83.11017 Boehringer Ingelheim Investigational Site
City
Chattanooga
State/Province
Tennessee
Country
United States
Facility Name
1218.83.11032 Boehringer Ingelheim Investigational Site
City
Grand Prairie
State/Province
Texas
Country
United States
Facility Name
1218.83.11030 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1218.83.11034 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1218.83.11021 Boehringer Ingelheim Investigational Site
City
Tomball
State/Province
Texas
Country
United States
Facility Name
1218.83.12011 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1218.83.12007 Boehringer Ingelheim Investigational Site
City
Edmonton
State/Province
Alberta
Country
Canada
Facility Name
1218.83.12001 Boehringer Ingelheim Investigational Site
City
Red Deer
State/Province
Alberta
Country
Canada
Facility Name
1218.83.12002 Boehringer Ingelheim Investigational Site
City
Paradise
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
1218.83.12009 Boehringer Ingelheim Investigational Site
City
St. John's
State/Province
Newfoundland and Labrador
Country
Canada
Facility Name
1218.83.12005 Boehringer Ingelheim Investigational Site
City
Kitchener
State/Province
Ontario
Country
Canada
Facility Name
1218.83.12006 Boehringer Ingelheim Investigational Site
City
London
State/Province
Ontario
Country
Canada
Facility Name
1218.83.12003 Boehringer Ingelheim Investigational Site
City
Smiths Falls
State/Province
Ontario
Country
Canada
Facility Name
1218.83.12010 Boehringer Ingelheim Investigational Site
City
Sudbury
State/Province
Ontario
Country
Canada
Facility Name
1218.83.12012 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Ontario
Country
Canada
Facility Name
1218.83.91003 Boehringer Ingelheim Investigational Site
City
Bangalore
Country
India
Facility Name
1218.83.91005 Boehringer Ingelheim Investigational Site
City
Chennai
Country
India
Facility Name
1218.83.91001 Boehringer Ingelheim Investigational Site
City
Mumbai
Country
India
Facility Name
1218.83.97004 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1218.83.97005 Boehringer Ingelheim Investigational Site
City
Haifa
Country
Israel
Facility Name
1218.83.97007 Boehringer Ingelheim Investigational Site
City
Holon
Country
Israel
Facility Name
1218.83.60001 Boehringer Ingelheim Investigational Site
City
Kelantan
Country
Malaysia
Facility Name
1218.83.60002 Boehringer Ingelheim Investigational Site
City
Perak
Country
Malaysia
Facility Name
1218.83.60003 Boehringer Ingelheim Investigational Site
City
Selangor, Malaysia
Country
Malaysia
Facility Name
1218.83.52004 Boehringer Ingelheim Investigational Site
City
Cuautla
Country
Mexico
Facility Name
1218.83.52001 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1218.83.52002 Boehringer Ingelheim Investigational Site
City
Guadalajara
Country
Mexico
Facility Name
1218.83.52005 Boehringer Ingelheim Investigational Site
City
Merida
Country
Mexico
Facility Name
1218.83.52003 Boehringer Ingelheim Investigational Site
City
Tampico
Country
Mexico
Facility Name
1218.83.63007 Boehringer Ingelheim Investigational Site
City
Cebu City
Country
Philippines
Facility Name
1218.83.63001 Boehringer Ingelheim Investigational Site
City
Cebu
Country
Philippines
Facility Name
1218.83.63008 Boehringer Ingelheim Investigational Site
City
Iloilo City
Country
Philippines
Facility Name
1218.83.63003 Boehringer Ingelheim Investigational Site
City
Iloilo
Country
Philippines
Facility Name
1218.83.63002 Boehringer Ingelheim Investigational Site
City
Marikina City
Country
Philippines
Facility Name
1218.83.63006 Boehringer Ingelheim Investigational Site
City
Marikina City
Country
Philippines
Facility Name
1218.83.63004 Boehringer Ingelheim Investigational Site
City
Quezon
Country
Philippines
Facility Name
1218.83.11037 Boehringer Ingelheim Investigational Site
City
San Juan
Country
Puerto Rico
Facility Name
1218.83.07001 Boehringer Ingelheim Investigational Site
City
Kazan
Country
Russian Federation
Facility Name
1218.83.07002 Boehringer Ingelheim Investigational Site
City
Petrozavodsk
Country
Russian Federation
Facility Name
1218.83.07004 Boehringer Ingelheim Investigational Site
City
Samara
Country
Russian Federation
Facility Name
1218.83.07006 Boehringer Ingelheim Investigational Site
City
Smolensk
Country
Russian Federation
Facility Name
1218.83.07003 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.83.07007 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.83.07005 Boehringer Ingelheim Investigational Site
City
Yaroslavl
Country
Russian Federation
Facility Name
1218.83.94004 Boehringer Ingelheim Investigational Site
City
Dehiwela
Country
Sri Lanka
Facility Name
1218.83.94002 Boehringer Ingelheim Investigational Site
City
Galle, Sri Lanka
Country
Sri Lanka
Facility Name
1218.83.94003 Boehringer Ingelheim Investigational Site
City
Kandy
Country
Sri Lanka
Facility Name
1218.83.94001 Boehringer Ingelheim Investigational Site
City
Ragama
Country
Sri Lanka
Facility Name
1218.83.66002 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
1218.83.66003 Boehringer Ingelheim Investigational Site
City
Bangkok
Country
Thailand
Facility Name
1218.83.66001 Boehringer Ingelheim Investigational Site
City
Muang, Khonkaen
Country
Thailand
Facility Name
1218.83.38007 Boehringer Ingelheim Investigational Site
City
Dnepropetrovsk
Country
Ukraine
Facility Name
1218.83.38001 Boehringer Ingelheim Investigational Site
City
Ivano-Frankivsk
Country
Ukraine
Facility Name
1218.83.38006 Boehringer Ingelheim Investigational Site
City
Kharkiv
Country
Ukraine
Facility Name
1218.83.38004 Boehringer Ingelheim Investigational Site
City
Odessa
Country
Ukraine
Facility Name
1218.83.38008 Boehringer Ingelheim Investigational Site
City
Vinnitsa
Country
Ukraine
Facility Name
1218.83.38003 Boehringer Ingelheim Investigational Site
City
Vinnytsya
Country
Ukraine
Facility Name
1218.83.38005 Boehringer Ingelheim Investigational Site
City
Vinnytsya
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
27684308
Citation
Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgrad Med. 2016 Nov;128(8):747-754. doi: 10.1080/00325481.2016.1238280. Epub 2016 Sep 29.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.83_U13-3654-01.pdf
Description
Related Info

Learn more about this trial

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

We'll reach out to this number within 24 hrs